

03-26-03-

1626

REV. 9/01  
For Other Than A Small Entity



RECEIVED  
MAR 31 2003  
TECH CENTER 1600/2900S  
VPI/98-4200S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Balasubramanian, Venkataraman  
Group Art Unit : 1626  
Inventors : Lauffer, David, et al.  
Serial No. : 10/039,898  
Filed : January 3, 2002  
Title : CYCLIZED AMINO ACID DERIVATIVES

Cambridge, Massachusetts  
March 25, 2003

Hon. Commissioner  
for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☐ a Supplemental Amendment;  
☒ a Reply to Restriction Requirement; ☐ Appendix I;  
☐ Petition for Extension of Time; ☐ a Supplemental  
Amendment; ☐ a substitute Specification; ☐ a Declaration;  
☐ a Supplemental Declaration; ☐ a Power of Attorney;  
☐ an Associate Power of Attorney; ☐ formal drawings; to be  
filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

☒ A fee for additional claims is not required.



Docket No.: VPI/00-129-5 US

Certificate Of Mailing Under 37 C.F.R. § 1.10

RECEIVED  
MAR 31 2003  
TECH CENTER 1600/2900

Express Mailing No. EU 709 892 026 US


Date of Deposit: February 5, 2003

I hereby certify that the following documents:

1. Response to Office Action and Amendment;
2. Appendix A; and
3. this return postcard receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington D.C. 20231

Karen DiRocco  
(type or printed name of person mailing document(s))

  
(signature of person mailing document(s))

☐ A fee for additional claims is required.

The additional fee has been calculated as shown below:

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	-	* =	X \$ 18 =	\$
INDEPENDENT CLAIMS	-	** =	X \$ 84 =	\$
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM			+ \$280 =	\$

\* If less than 20, insert 20. TOTAL \$

\*\* If less than 3, insert 3.

☐ A check in the amount of \$\_\_\_\_\_ in payment of the filing fee is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

#### EXTENSION FEE


☐ The following extension is applicable to the Response filed herewith; ☐ \$110.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$410.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ \$930.00

extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,450.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); \$1,970.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).

☐ A check in the amount of ☐ \$110.00; ☐ \$410.00; ☐ \$930.00; ☐ \$1,450.00; ☐ \$1,970.00 in payment of the extension fee is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

☐ Please charge the ☐ \$110.00; ☐ \$410.00; ☐ \$930.00; ☐ \$1,450.00; ☐ \$1,970.00; extension fee to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

  
\_\_\_\_\_  
Nandakumar Govindaswamy  
Limited Recognition  
Attorney for Applicants

VERTEX PHARMACEUTICALS INCORPORATED  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel.: (617)444-6619



RECEIVED


BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE  
MAR 31 2003  
TECH CENTER 1600/2900

**LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)**

Nandakumar Govindaswamy is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Vertex Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein the patent application is assigned to Vertex Pharmaceuticals, Inc., and the attorney or agent of record in the applications is a registered practitioner who is an employee of Vertex Pharmaceuticals, Inc. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Nandakumar Govindaswamy ceases to lawfully reside in the United States, (ii) Nandakumar Govindaswamy's employment with Vertex Pharmaceuticals, Inc. ceases or is terminated, or (iii) Nandakumar Govindaswamy ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: June 30, 2003**

  
\_\_\_\_\_  
Harry Moatz,  
Director of Enrollment and Discipline